Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

FTSE 250 Genomics Breakout: Oxford Nanopore Technologies (LSE:ONT) Hits One-Year High as New Leadership and Insider Buying Spark Rerating

The rally has become a major talking point acrossInvestmentplatforms and social media, where investors are debating whether the business has reached a turning point under its newLeadershipteam. With the share count now at nearly 981 million following monthly option exercises, the company'sMarket Valuehas climbed …

Ankur Sharma | 04 November 2026

FTSE 250 Gene Therapy Rebuild: Can Oxford Biomedica (LSE:OXB) Turn Record Client Wins Into a 2027 Growth Surge?

With the final weeks of the year approaching, the market is focused on two big questions: can OXB deliver within its revised 2026 range, and how much visibility does it have on the steep growth it is promising for 2027? Debate onInvestmentplatforms andSocial Mediahas …

Ankur Sharma | 04 November 2026

FTSE 250 Healthcare Trust Trades at a Premium: Polar Capital Global Healthcare Trust (LSE:PCGH) Reissues Shares Near Record Highs

The FTSE 250 trust has become a talking point among investors looking for exposure to the global healthcare sector, which has rebounded after a difficult period of pressure from drug pricing, tariffs and regulatory concerns. With the shares close to their 52-week high, investors …

Ankur Sharma | 04 November 2026

FTSE 250 Healthcare Investment Trust Worldwide Healthcare Trust (LSE:WWH) Back in Focus as Global Health Stocks Stage a Comeback

The trust's half-year results, covering the six months to 30 September 2026, are expected shortly and will show how its portfolio has performed during the recovery.

Ankur Sharma | 04 November 2026

Convatec (LSE:CTEC) in Focus: Cfo Succession And Board Changes Puts FTSE 100 Investors on Alert

The centralInvestmentquestions concernBusinessfundamentals, financial flexibility and how the development affects future performance.

Ankur Sharma | 04 November 2026

HUTCHMED (LSE:HCM) in Focus: Regulatory Filings Accepted For Review Puts AIM-listed Investors on Alert

The centralInvestmentquestions concern approval milestones, clinical evidence and how the development affects future performance.

Ankur Sharma | 04 November 2026

HUTCHMED (LSE:HCM) in Focus: Sovleplenib Orphan Drug Designation Puts AIM-listed Investors on Alert

The centralInvestmentquestions concernBusinessfundamentals, financial flexibility and how the development affects future performance.

Ankur Sharma | 04 November 2026

International Biotechnology Trust (LSE:IBT) in Focus: Final Results Puts London-listed Investors on Alert

The centralInvestmentquestions concern profit quality, segment margins and how the development affects future performance.

Ankur Sharma | 04 November 2026

Oxford Nanopore Technologies (LSE:ONT) in Focus: Equity Issuance Puts London-listed Investors on Alert

The centralInvestmentquestions concern dilution, funding flexibility and how the development affects future performance.

Ankur Sharma | 04 November 2026

Can Oncology Power AstraZeneca to Its $80 Billion Ambition?

AstraZeneca Plc shares rose 0.75% to around 13,964.0p today, a gain of 104.00p, according to the supplied market data.

Ankur Sharma | 03 November 2026
Support

Hi! How can we help you today?

Loading…